according bloomberg eli lilly co third quarter profit rose percent sales cymbalta antidepressant almost doubled net income rose million cents share million cents year earlier company said statement pr newswire result beat analyst estimates revenue cymbalta percent million benefited lilly reorganized sales force focus market depression drugs cymbalta continues show exceptionally strong growth new prescription levels currently percent late levels `` ryan wrote oct report investors lilly also said sales zyprexa schizophrenia drug declined percent stabilized sales zyprexa rose percent billion first increase recorded drug least six quarters drug provided percent company total sales zyprexa benefited pricing increases offsetting double digit prescription declines `` said chris shibutani jp morgan securities analyst new york oct report investors july state mississippi joined three states suing lilly zyprexa saying drugmaker fraudulently touted zyprexa unapproved uses including children hid drug potential hazards including excessive weight gain increased risk diabetes lilly agreed settle personal injury complaints related drug million faces additional claims must evidence piling indicating cymbalta much safe effective antidepressants perhaps i post evidence regarding hot selling medication i see lilly keeps jacking price zyprexa lawsuits pretty pricey justify existence link bloomberg article